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Toxicology: Judge Data or Dollars?
The knowledge gained by our work as toxicologic scientists ranges
from molecular mechanisms to clinical signs oftoxicity, from physi-
ologically based pharmacokinetics to tumor counts. Any of this
research, from any source, may be translated into regulatory action
in order to protect the public and the environment; thus, society is
best served by the best science from every source. The challenge is to
find the criteria to accurately and, increasingly, quickly judge which
studies are valid and appropriate to affect regulation. Cynics make
these quick judgments based on funding sources; traditionalists trust
the proven, but slow, peer-review process; regulatory agencies want
to see raw data from industry, but have implicitly trusted and
exempted academia from this scrutiny. Needs for confidentiality
place limits on disclosure, but they do not preclude a more even and
open approach to data from all sources. Greater disclosure will
result in a scientific process that is faster, better, and more trustwor-
thy-"trust" is the key word here. But, as a former U.S. president
said near the end ofthe Cold War, "Trust but verify."
Verification was the apparent goal ofa few lines buried deep in
the voluminous 1999 Omnibus Spending Bill (1). It states
That the Director of OMB amends section -.36 of OMB Circular A-1 0 to
require Federal awarding agencies to ensure that all data produced under an
award will be made available to the public through the procedures established
under the Freedom ofInformation Act.
This new law has provoked, according to one editorial, "...howls
of protest from scientists, their institutions, and the federal agen-
cies that fund scientific research" (2). However, major scientific
societies, including the American Chemical Society, the Council
for Chemical Research, and the American Association for the
Advancement of Science, all support, in principle, the need to
assess the validity ofsuch research results (3). Recently, it has again
been made clear that the issues ofquality and reliability oftoxicolo-
gy data and its reasoned interpretation for regulatory purposes are
critical (4); the question is how best to accomplish that end.
Researchsh3oiukldbejudgedoni the basisoJfstc.ientific
merit, without regardlforfundlinigsource or- wlhere the
studies are conducted..,
[Society ofToxicology. SOT Principles for Research Priorities in Toxicology.
Available: http://www.toxicology.org/AboutSOT/about.html (1999).]
The tried and true
way, the unfettered
peer-review process,
is and will continue
to be the keystone
of scientific pro-
F gress. However, it
rarely depends on
the scrutiny of raw
data; rather, the
peer-review process
_ 1 _ ultimately depends
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replication of
important findings. Thus, it is slow, sometimes painfully so.
Democracy is a similarly empirical endeavor. Like science, the
process is generally ponderous and tentative, and our laws are often
badly out of synchronization with science, a condition regularly
exacerbated by swells of public concern. Fueled by a willing press,
the public perception of a crisis can rapidly propel new regulations
that may never gain a scientific foundation, nor are they repealed
when science catches up. Rational or not, an alarmed public, or
more often issue advocacy groups, call for immediate action well
before any reasoned assessment ofwhat action, if any, is called for.
The scientific community is left unprepared. Poor decisions follow,
which may have unintended consequences, levy unnecessary
expense on taxpayers, and provide no demonstrable benefit for pub-
lic health or the environment.
Unfortunately, as a preventative for bad regulation based on
unvalidated or preliminary science, the new amendment to Circular
A-1 0 is a crude vaccine that will cause more problems than it
could possibly cure. The apparent intent of the law is laudable, but
its shortcomings are serious: It lacks adequate protection for intel-
lectual property, patient privacy, and against legal abuse by those
who might be tempted to harass researchers with unreasonable
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demands. Work in progress is not protected. Nevertheless, we
believe that the raw data of all scientific studies, regardless of
source-government, academia, or commercial enterprise-
should be made available for rigorous outside examination before
the conclusions may be used to justify any law or regulation. A
scientist's intent or lack ofintent to influence government is irrel-
evant; what must invoke data disclosure is the government's
intent to use the conclusions. And without such scrutiny, law-
makers and regulators should not be allowed to take advice from
the study.
Formulating a better law, or amending the requirements of
A-1 0 by OMB, necessitates thoughtful deliberation and sensi-
tivity. Such action must consider the attributes and complex
relationships of academia, funding institutions, private enter-
prise, and other stakeholders, as well as the speedy verification
necessary in the age ofinformation. It will require that all parties
acknowledge what still works and what should be improved. It
will require that we embrace reasonable change as we face the
dissolution ofyet another comfortable status quo.
Like bitter medicine that is good for you, 20 years ofregula-
tory oversight has been good for the integrity and credibility of
industrial research. In the mid-1970s, the U.S. Environmental
Protection Agency (EPA) and Food and Drug Administration
defined stringent and detailed standards for conducting sound
laboratory science in response to a widely publicized case offraud
in a contract toxicology laboratory. Good Laboratory Practices
(GLP) were adopted and have been applied to studies submitted
for regulatory consideration since 1979 (5). GLP requirements
include, for example, retaining raw data for 10 years or for the
life of the product. This requirement is routinely exceeded. In
our toxicology laboratory at Dow Chemical, the Standard
Operating Procedure (SOP) manual dictates that durable speci-
mens such as paraffin tissue blocks, glass slides, and all original
data are saved for their useful life or 75 years, whichever is longer.
Thus, no material ofpotential use to reconstruct a study has been
discarded for many years. In this respect, Dow is apparently typi-
cal; an informal polling ofother industrial labs revealed none that
had discarded potentially useful raw data from their archives.
Other details saved in GLP study records include the curricu-
lum vitae and signature samples ofall study personnel; analyses of
test material for identity, purity, homogeneity, and stability in
the carrier; the record of randomization by weight of incoming
test animals and their daily observations throughout the study;
any amendments to the signed study protocol; and the location of
all archived materials. We are assisted in compliance by Dow's
Quality Assurance Unit (QAU), a group under separate line man-
agement (also a GLP requirement) whose job it is to ensure that
each action specified by our SOP manual and study protocol is,
in fact, carried out. Deficiencies are reported by the QAU to lab-
oratory management-they tell your boss. So, when EPA inspec-
tors show up unannounced (as they can and do) to inspect our
facilities, personnel records, and raw data, we are always ready.
The integrity of the study file and research process speaks for
itselfand gives us and regulators, and ultimately the public, con-
fidence in our results.
We are not advocating that academic research be performed
under the yoke ofGLP law; that would be an unnecessary, coun-
terproductive encumbrance that would impede scientific creativ-
ity if applied as a blanket regulation. Those encumbrances are
why mechanistic and other nonguideline studies, even in indus-
try, are often not designed to meet every GLP requirement. On
the other hand, understanding and always applying principles of
good record keeping to a practical extent prepares any scientist
for outside scrutiny-scrutiny we believe is justified for science
that may impact regulation. The GLPs were meant to counteract
the bias generated by profit motives, but no objective analysis
would conclude that this is the only bias industrial scientists live
with, nor that industrial scientists are the only ones who live
with potentially confounding influences.
There are a number of significant sources of bias that frame
the way toxic risks and hazards are communicated. Perhaps the
most important, but least obvious, is the bias of purpose. Both
academic and industrial scientists are interested in hazard identi-
fication (learning what effects a chemical has at toxic doses) and
in understanding the mechanisms of the effects. However,
industrial and governmental scientists have a special need to
answer the more practical question: At what dose is there no sig-
nificant effect? Establishing a no-observed-effect level in a wide
variety of studies provides the most vital information for deter-
mining safe exposure levels. This is not glamorous research, but
it is GLP research, and it is reliable.
Cultural biases also loom large. For academics, publication is a
primary product; sharing knowledge is perhaps the central satisfac-
tion of university culture. For industrial toxicologists the product
is the saleable product, and publications support products. The
majority of our work is directed toward licensing new chemicals
for commerce; companies are understandably protective of this
valuable intellectual property. These reports and reams ofsupport-
ing data are reviewed by the agencies, but are seldom submitted to
peer-reviewed journals. However, much similar work concerns
established drugs and chemicals, and much of that work never
reaches the journals either. More ofthis research could be subject-
ed to the rigors of the peer-review process, which would increase
the credibility of industrial toxicology, improve communications,
and benefit all parties. Toxicology could also benefit from more
editorial and review articles from our quarter. Publication needs to
become a more central part of our culture, but another source of
bias should be acknowledged.
Journals have their biases; the most overt in toxicology is the
preference for "positive results," and guideline studies often pro-
duce few toxic or novel effects, especially at relevant doses.
However, a study with positive findings performed by an unnat-
ural route of administration-for example, intraperitoneal injec-
tion of a material metabolized by the liver and found in minute
concentrations in the diet-while ofdubious value for risk assess-
ment (6), may be more likely to find its way into the literature
than a more relevant dietary study showing negative results with
the same material. This bias against the dull, although under-
standable and perhaps defensible from a journal marketing per-
spective, needs to be more widely and deeply appreciated.
Negative findings from realistic studies make a positive contribu-
tion to the shape of a dose-response curve and, more important-
ly, provide context for positive studies; thus, they are vital for
unbiasedjudgment.
In part because ofthe GLP rules, the cynical beliefthat profit
motives must bias the data ofindustrial scientists toward minimiz-
ing findings on safety studies is not generally shared by the regula-
tory scientists who receive our reports and verify our conduct.
Long experience has taught the chemical industry that cooperation
is key and that safety and good science are the friends of profit.
This is because, GLPs and simple scruples aside, the consequences
for industry of either under- or overinterpreting data can be
extremely expensive-expensive because a good, safe product
might never be made or expensive because an unsafe product
might hurt people or the environment and generate lawsuits.
These are strong but often unappreciated, mutually neutralizing
biases that together favor an honest assessment ofthe data. This is
why the assumption ofa simple profit-driven bias that pollutes the
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publications of industrial scientists is wrong. Nevertheless, this
misperception is common enough that the Society of Toxicology
(6,K) issued this policy statement:
Research shotuld be judged oni the basis ofscientific merit, without regard for
funding source or where the studies are conducted (e.g., academia, govern-
ment or industry).
This call for fairness was not inspired solely by unwarranted
cynicism directed at industry, but by the too-common dismissal of
unwelcome findings from any source perceived to have a bias differ-
ent from one's own.
There are other significant financial interests that can affect bias,
and they are relatively unmitigated and often favor alarmist interpre-
tations. These include the way mass media profit from the insatiable
public appetite for sensation and conflict, the highly competitive aca-
demic grant process that sometimes favors overstatement of toxic
threats, the hyperbolic fund-raising pleas of some activist organiza-
tions, and even within big corporations, the conservative way legal
departments assess risks oflitigation.
There is no simple way to eliminate all ofthese biases. Perhaps the
best solution is to recognize them collectively as a form ofdiversity and
embrace them as alternative points ofview that ultimately strengthen
our collective understanding. But, to avoid the postmodern pitfall that
says truth is relative, that reality bends to assertion, we can only fall
back on our common training as scientists: We can ask to see the data.
As scientists, our bias should be toward universal candor in the
scientific process, and we should recognize this stance as identical
with the ideals ofthe democratic process. We need a carefully crafted,
more focused law, one written to ensure that all research impacting
on regulatory decisions is examined and verified while protecting the
legitimate concerns of the whole scientific community. Such a law
may slow the wheels ofscience a little, but they will spin far less as we
all progress more surely toward the truths that exist quite independent
of our limited perceptions and opinions. When we stand on less
uneven ground in this age ofdisclosure, the credibility ofall toxicolo-
gists will rise. When the diamonds oftruth are brought fully into the
light, with every facet seen clearly, the question of funding sources
will seem dull indeed.
James W. Crissman
James S. Bus
Ron R. Miller
Dow Chemical Company
Midland, Michigan
E-mail: jbus@dow.com
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